Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Aug 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better understand bone and muscle health in people who are at risk for conditions like osteoporosis, which causes bones to become weak and more likely to break. Researchers will use advanced imaging devices to look closely at the structure of bones and muscles in patients with various health issues, such as rheumatoid arthritis or neurological disorders. The goal is to gather important information that can help predict fracture risks more accurately than current methods, which often miss key details about bone structure.

To participate in the study, individuals must be between the ages of 65 and 74 and have certain conditions that put them at risk for osteoporosis, such as a history of brittle bone fractures or specific diseases like rheumatoid arthritis or chronic kidney disease. Participants will have their bone and muscle health assessed using special imaging techniques, and they will be contributing to research that could lead to better ways to manage bone health and reduce the chances of fractures in the future. It's important to note that individuals on certain medications or with specific medical histories may not be eligible for the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• For the patients:
• Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies:
• • Osteoporosis defined by: History of a documented brittle bone fracture
• • Bone fragility: Patient with indication for bone densitometry but no history of fracture
• * Inflammatory joint disease:
• • Rheumatoid arthritis
• • Spondyloarthritis
• • Chronic kidney disease
• * Endocrinopathies:
• • Primary hyperparathyroidism
• • Constitutional thinness
• • Anorexia nervosa
• • Obesity (BMI \>30)
• • Sarcopenia
• • Neuropathies - Parkinson's disease
• For the controls:
• • Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent
• Exclusion Criteria:
• • No sign written consent
• For the controls:
• * Medications inducing bone loss:
• • anti-aromasin or GnRH agonist for at least 6 months,
• • corticosteroids (dose ≥ 5 mg/d for 6 months)
• • anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)
• • History of fracture due to bone fragility
• • Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)